The development of gene therapy has allowed the potential treatment and prevention of many genetic diseases to become a reality. Lung cancer is a disease that can potentially be treated by gene therapy, as present day therapeutics have little effect. A key to the successful use of gene therapy is the development of efficient nucleic acid delivery systems. The goal of this project is to develop a non-viral, DNA/protein complex that utilizes a lung cancer cell specific ligand for the selective delivery of ionically attached nucleic acids. Initially, epidermal growth factor (EGF) will be used as the targeting ligand and will be modified by one of several different chemical reactions, to attach the polycation, poly- L-lysine (PLL) to the ligand. This EGF/PLL conjugate will then be tested for the ability to bind DNA, a polyanion. Once optimum conditions are achieved for DNA binding, the complexes will be tested for the ability to deliver genes into cells both in vitro and in vivo. Since the EGF/DNA complex is internalized by a receptor-mediated pathway, various endosomal lysis agents will be used to by-pass the normal degradation that occurs in this pathway. In the event that EGF cannot be used, other ligands will be tested such as transferrin or monoclonal antibodies specific for lung cancer cell receptors. Two tumor cell lines, which express either high or low levels of the EGF receptor, will be used in the analysis in vitro. The DNA/protein complexes will also be administered and tested in vivo by injection through one of several routes to lung tumors that have been generated in nude mice. Since a large majority of lung tumors are deficient in the expression of the tumor suppressor p53, a plasmid that expresses p53 will be delivered into the lung tumor cells and tested for the ability to promote cancer cell death. The p53 gene will also be cloned into a plasmid that replicates episomally to ensure that the plasmid will exist in the cancer cell for the life of the cell.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29CA066037-03
Application #
2008711
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1995-01-03
Project End
1999-12-31
Budget Start
1997-01-01
Budget End
1997-12-31
Support Year
3
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Surgery
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Cristiano, R J (1998) Viral and non-viral vectors for cancer gene therapy. Anticancer Res 18:3241-5
Cristiano, R J (1998) Targeted, non-viral gene delivery for cancer gene therapy. Front Biosci 3:D1161-70
Xu, B; Wiehle, S; Roth, J A et al. (1998) The contribution of poly-L-lysine, epidermal growth factor and streptavidin to EGF/PLL/DNA polyplex formation. Gene Ther 5:1235-43
Cristiano, R J; Xu, B; Nguyen, D et al. (1998) Viral and nonviral gene delivery vectors for cancer gene therapy. Cancer Detect Prev 22:445-54
Roth, J A; Cristiano, R J (1997) Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 89:21-39
Nguyen, D M; Wiehle, S A; Koch, P E et al. (1997) Delivery of the p53 tumor suppressor gene into lung cancer cells by an adenovirus/DNA complex. Cancer Gene Ther 4:191-8
Nguyen, D M; Wiehle, S A; Roth, J A et al. (1997) Gene delivery into malignant cells in vivo by a conjugated adenovirus/DNA complex. Cancer Gene Ther 4:183-90
Cristiano, R J; Roth, J A (1996) Epidermal growth factor mediated DNA delivery into lung cancer cells via the epidermal growth factor receptor. Cancer Gene Ther 3:4-10
Nguyen, D M; Spitz, F R; Yen, N et al. (1996) Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg 112:1372-6;discussion 1376-7